Clinical Trial Update: A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 [Phase 3]

View source ↗

Summary

Phase 3 trial of PS-341 (bortezomib) in patients with multiple myeloma who progressed after dexamethasone has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• PS-341 (bortezomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED